Thus, it remains uncertain whether loss or preservation of agrin expression is as clear-cut for the distinction between well-differentiated cholangiocarcinomas and metastatic pancreatic carcinomas as it is for poorly differentiated ones. This evidence concerns the gene AGRN and exocrine pancreatic carcinoma.